No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $60
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), COMPASS Pathways (CMPS) and Cogstate Ltd (OtherCOGZF)
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $45
PTC Therapeutics (PTCT) Receives a Hold From Leerink Partners
Express News | PTC Therapeutics Inc : Leerink Partners Cuts Target Price to $45 From $50
PTC to Announce Fiscal Q1'25 Results on Wednesday, February 5th, 2025